UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________ FORM 10-K _________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023. or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41358 ACLARION, INC. (Exact name of registrant as specified in its charter) Delaware 47-3324725 (State or ...

Confirms predictive value of Nociscan for identifying painful discs. Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons. BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians ...

BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, ...

BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants ...

Aclarion (NASDAQ:ACON) stock is falling on Monday after the healthcare technology company revealed plans for a public offering of its shares.Aclarion intends to offer up to 3,888,888 units in this offering. Each of these units will contain one share of ACON stock and a warrant to acquire another share.The finer details of the public offering still aren’t available. While the company has an assumed price of $1.80 per unit, that’s not concrete. It also hasn’t revealed the exercise price of the warrants in the ...

Exhibit 99.1 INDEX TO FINANCIAL STATEMENTS Aclarion, Inc. Page Financial Statements Report of Independent Registered Public Accounting Firm - Haynie & Company LLP (ID# 457) F-2 Report of Independent Registered Public Accounting Firm CohnReznick LLP (ID# 596) F-3 Balance Sheets at December 31, 2023 and 2022 F-4 Statements of Operations, for the Years Ended December 31, 2023 and 2022 F-5 Statements of Changes in Stockholders’ Equity (deficit), for the Years Ended December 31, 2023 and 2022 F-6 Statements of C ...

Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning 5 additional Key Opinion Leader (KOL) surgeons expected to adopt Nociscan through the Alphatec strategic partnership in 1H24 BROOMFIELD, CO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is l ...

Stock Issuance and Dilution - Aclarion issued 500,000 shares of ACON stock in exchange for $1,185,226 of principal and accrued interest on unsecured non-convertible notes, increasing the total number of outstanding shares to 1,791,375 [1] - The company may enact similar exchanges in the future to cover financing from those notes [1] - Increasing the total number of shares often results in a stock's price falling due to dilution of current investors' stakes [1] ACON Stock Performance - ACON stock is down 15.5% as of Monday morning, with about 367,000 shares traded compared to the daily average trading volume of 1.2 million shares [2] - The stock was down 14.4% year-to-date as of Friday's close [2] Market Context - The article mentions other stocks such as SoFi Technologies (NASDAQ:SOFI), Panbela Therapeutics (NASDAQ:PBLA), and Revelation Biosciences (NASDAQ:REVB) as part of the broader stock market news [2] - InvestorPlace typically avoids publishing commentary on companies with a market cap of less than $100 million or trading less than 100,000 shares daily due to the risks associated with low-volume stocks [3]

Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute Dr. Uribe Becomes Aclarion's 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligenc ...

Partnership aims to include Aclarion's surgical decision support technology within ATEC's AlphaInformatiX platform to better inform spine surgery Aclarion's Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine to help physicians identify the location of chronic low back pain BROOMFIELD, CO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveragi ...